SEC Form 4 · accession 0001493152-18-001223
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jan 25, 2018
Accepted (ET)
Jan 29, 2018 · 9:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 25, 2018 | S | 205,144 | $5.45 | D | 3,160,284 | I | See Footnote 1 |
| Common StockF1 | Jan 26, 2018 | S | 39,300 | $5.35 | D | 3,120,984 | I | See Footnote 1 |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F110X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. 10X Capital Management, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.